Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2022-03-21
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, phase 1, sequential dose escalation study. AMG 673 will
be evaluated as a short term intravenous (IV) infusion in adult subjects with
relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United
States, Australia and Germany.